Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
AstraZeneca
Colorcon
Boehringer Ingelheim

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,251,910

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,251,910
Title: 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Abstract:Compounds of formula having the following stereochemistry ##STR1## wherein R, R.sup.1, R.sub.2, R.sup.3 and R.sup.4 are as defined in the specification. The compounds are useful as P.sub.2T receptor antagonists.
Inventor(s): Guile; Simon (Loughborough, GB), Ingall; Anthony (Loughborough, GB), Springthorpe; Brian (Loughborough, GB), Willis; Paul (Nottingham, GB)
Assignee: AstraZeneca UK Limited (London, GB)
Application Number:09/155,023
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,251,910
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,251,910

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,251,910

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9702773Jul 22, 1997
PCT Information
PCT FiledJuly 15, 1998PCT Application Number:PCT/SE98/01393
PCT Publication Date:February 04, 1999PCT Publication Number: WO99/05143

International Family Members for US Patent 6,251,910

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 017014   Start Trial
Argentina 077553   Start Trial
Austria 251161   Start Trial
Australia 745381   Start Trial
Australia 8370698   Start Trial
Brazil 9810802   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Express Scripts
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.